HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial.
OBJECTIVES FM is a condition that preferentially affects women . Sex hormones , and in particular oestrogens , have been shown to affect pain processing and pain sensitivity , and oestrogen deficit has been considered a potentially promoting factor for FM . However , the effects of oestrogen treatment in patients suffering from FM have not been studied . Here , we examined the effect of transdermal oestrogen substitution treatment on experimental as well as self-estimated pain in women suffering from FM . METHODS Twenty-nine post-menopausal women were r and omized to either 8 weeks of treatment with transdermal 17β-oestradiol ( 50 µg/day ) or placebo according to a double-blind protocol . A self-estimation of pain , a set of quantitative sensory tests measuring thresholds to temperature , thermal pain , cold pain and pressure pain , and a cold pressor test were performed on three occasions : before treatment , after 8 weeks of treatment and 20 weeks after cessation of treatment . RESULTS Hormonal replacement treatment significantly increased serum oestradiol levels as expected ( P < 0.01 ) . However , no differences in self-estimated pain were seen between treatment and placebo groups , nor were there any differences between the two groups regarding the results of the quantitative sensory tests or the cold pressor test at any of the examined time points . CONCLUSION Eight weeks of transdermal oestradiol treatment does not influence perceived pain , pain thresholds or pain tolerance as compared with placebo treatment in post-menopausal women suffering from FM . TRIAL REGISTRATION Clinical Trials.gov Registration ; http://www . clinical trials.gov ; NCT01087593
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .